# Genome-wide mutational integration for ultra-sensitive plasma tumor burden monitoring in immunotherapy

> **NIH NIH R01** · WEILL MEDICAL COLL OF CORNELL UNIV · 2022 · $658,506

## Abstract

PROJECT SUMMARY
A major gap in cancer diagnostics is that state-of-the-art imaging and other existing methods fail to reliably detect
low levels of cancer known as minimal residual disease (MRD), which remain following surgical resection of
early-stage tumors or treatment of advanced disease. Left untreated, MRD can proliferate and result in lethal
cancer recurrence. Hence, there is a critical need to sensitively detect MRD in order to optimize adjuvant
therapies or precision immunotherapy. Liquid biopsy offers the ability to noninvasively monitor MRD by detecting
circulating tumor DNA (ctDNA) originating from cancer cells. Nonetheless, detection of ctDNA is challenging due
to extremely low levels of ctDNA in low-burden disease. The prevailing paradigm argues for deep targeted
sequencing of informative loci. However, we have shown that this approach faces fundamental barriers to
sensitivity due to the low amount of available DNA in typical plasma samples, which imposes a physical ceiling
on depth of sequencing. To overcome this challenge, our interdisciplinary team of geneticists, computer
scientists, and oncologists developed MRDetect, an orthogonal approach for ctDNA detection based on
genome-wide mutation aggregation of single-nucleotide variants (SNVs) and copy number variants (CNVs) using
whole-genome sequencing (WGS) of plasma. MRDetect enables ultra-sensitive MRD detection down to one part
in a hundred thousand, and we have demonstrated its ability to detect MRD shortly after surgery or treatment in
colorectal cancer, melanoma and non small-cell lung cancer (NSCLC). Our objective in this project is to develop
crucial advances that will foster broad-based adoption of this technology across cancer settings. First, we
propose to incorporate advanced machine learning (ML) framework known as ‘deep learning’ (DL) into the
MRDetect platform to enable SNV identification in plasma WGS in low tumor burden settings (Aim 1). This will
yield MRDetect-DL, which we anticipate will significantly improve cancer detection at low tumor levels through
a >100-fold improvement in signal to noise enrichment compared to MRDetect. MRDetect-DL performance will
be tested in high-risk post-operative melanoma to define the need for adjuvant therapy, as well as in advanced
melanoma treated with immunotherapy for precision immunotherapy applications. Critically, MRDetect-DL will
obviate MRDetect’s need for a matched tumor sample, ensuring broad adoption across different clinical settings.
Second, we posit that in addition to SNV-based advances, MRDetect’s sensitivity can be increased by enhanced
detection of CNVs, as these are broadly observed in solid tumors. We propose to develop MRDetect-CNV, an
ML-denoising technique to ultra-sensitively detect small CNVs using plasma WGS (Aim 2). We will test
MRDetect-CNV on NSCLC plasma samples from patients undergoing neoadjuvant immunotherapy to define its
ability to predict treatment response. Impact: Pairing MRDetect-DL with M...

## Key facts

- **NIH application ID:** 10344658
- **Project number:** 1R01CA266619-01
- **Recipient organization:** WEILL MEDICAL COLL OF CORNELL UNIV
- **Principal Investigator:** Dan Landau
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $658,506
- **Award type:** 1
- **Project period:** 2022-06-01 → 2027-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10344658

## Citation

> US National Institutes of Health, RePORTER application 10344658, Genome-wide mutational integration for ultra-sensitive plasma tumor burden monitoring in immunotherapy (1R01CA266619-01). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10344658. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*